Today, researchers from the University of Colorado Health Sciences Center, along with colleagues from Stanford University, report the results of a large-scale, genome-wide study to investigate gene copy number differences among ten primate species, including humans.
A drug initially used to treat mild to moderate Alzheimer’s disease improved the memory and global function of people with severe Alzheimer?s disease and was safe and effective, according to a study published in the July 31, 2007, issue of Neurology?, the medical journal of the American Academy of Neurology.
Women who experienced cognitive decline over a 13 to 15 year period after age 65 were more likely to sleep poorly than women whose cognition did not decline, according to a study led by researchers at the San Francisco VA Medical Center (SFVAMC).
Every kid knows that moms have “eyes in the back of their heads.” We are adept at fixing our gaze on one object while independently directing attention to others. Salk Institute neurobiologists are beginning to tease apart the complex brain networks that enable humans and other higher mammals to achieve this feat.
After six to nine months of abstinence from alcohol, recovering alcoholics who were also chronic smokers showed a significantly lower rate of improvement in tests of memory, reasoning, judgment, and visual/spatial coordination than non-smoking recovering alcoholics in a study conducted by researchers at the San Francisco VA Medical Center (SFVAMC).
Penn State Milton S. Hershey Medical Center today announced that James McInerney, M.D., associate professor of neurosurgery, and director of stereotactic and functional neurosurgery, Penn State Hershey Medical Center and Penn State College of Medicine, in collaboration with Elana Farace, Ph.D., neuropsychologist, associate professor of neurosurgery and director of clinical research, will receive the New Investigator Award for their research in vagus nerve stimulation (VNS) therapy at the New Clinical Drug Evaluation Unit (NCDEU) meeting on Monday, June 11, in Boca Raton, Florida.
Medivation, Inc. (NASDAQ: MDVN) announced that the benefits of Dimebon over placebo in its double-blind, placebo-controlled Phase 2 study in mild-to- moderate Alzheimer’s disease were statistically significant on all five study endpoints at 12 months.
Alzheimer’s disease researchers may be able to reduce the time and expense associated with clinical trials, according to early results from the Alzheimer?s Disease Neuroimaging Initiative (ADNI), a public-private research partnership organized by the National Institutes of Health. Preliminary results from ADNI show how it might yield improved methods and uniform standards for imaging and biomarker analysis, so these techniques can be employed in the fight against Alzheimer?s disease.
Can a fitness program for your brain improve thinking and concentration the way lifting weights can increase muscle strength?
Two genes important for human development and implicated in cancer and schizophrenia also help keep a healthy balance between excitation and inhibition of brain cells, researchers say.